X4 pharmaceuticals, inc (ASNS)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Dec'16
Assets
Current assets:
Cash and cash equivalents

115,054

126,184

76,251

90,180

22,299

8,134

40,753

49,940

63,999

76,793

3,035

Accounts receivable

3,000

0

-

-

-

-

-

-

-

-

-

Grant and incentive receivables

-

-

-

-

-

-

2,870

2,178

1,926

1,608

1,345

Restricted cash

-

-

-

3,163

-

-

51

51

51

0

-

Research and development incentive receivable

416

1,998

1,730

1,708

1,552

0

-

-

-

-

-

Prepaid expenses and other current assets

3,480

1,096

1,234

1,598

2,372

1,205

1,260

4,393

2,549

1,129

1,336

Total current assets

121,950

129,278

79,215

96,649

26,223

9,339

44,934

56,562

68,525

79,530

5,716

Property and equipment, net

475

403

348

258

271

241

323

353

384

421

519

Intangible assets

-

-

-

4,900

4,900

-

-

-

-

-

-

Goodwill

27,109

27,109

27,109

27,109

27,407

0

-

-

-

-

-

Right-of-use assets

1,803

1,959

2,110

2,187

2,705

-

-

-

-

-

-

Restricted cash, non-current

-

-

755

2,298

947

-

543

295

312

355

394

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

9

Other assets

2,380

1,949

-

106

96

364

101

-

-

948

966

Total assets

153,717

160,698

109,537

133,507

62,549

9,944

45,901

57,210

69,221

81,254

7,604

Liabilities, Convertible Preferred Stock, Redeemable Common Stock and Stockholders’ Equity (Deficit)
Liabilities, Convertible Preferred Stock, Redeemable Common Stock and Stockholders’ Equity
Current liabilities:
Accounts payable

1,248

2,088

1,704

3,099

6,132

2,969

2,126

2,137

1,108

1,893

1,645

Accrued expenses

5,786

6,461

5,697

5,094

4,179

3,251

3,092

3,879

5,141

5,779

2,156

Current portion of lease liability

916

898

878

860

841

-

-

-

-

-

-

Current portion of long-term debt, net of discount

-

-

0

4,151

5,298

1,687

-

-

-

-

-

Unearned income

-

-

-

-

-

-

727

712

730

694

504

Loans payable, net of discount

-

-

-

-

-

-

2,908

3,486

2,318

2,314

2,299

Convertible promissory notes, net of discount

-

-

-

-

-

-

-

-

-

-

2,863

Derivative liability

-

-

-

-

-

-

-

-

-

-

2,593

Total current liabilities

7,950

9,447

8,279

13,204

16,450

7,907

8,853

10,214

9,297

10,680

12,060

Preferred stock warrant liability

-

-

0

-

-

4,947

-

-

-

-

-

Long-term debt, including accretion, net of discount and current portion

-

-

-

-

-

8,145

-

-

-

-

-

Long-term debt, including accretion, net of discount and current portion

25,266

20,097

19,986

21,748

13,365

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

417

-

-

-

-

-

Lease liability

1,684

1,918

2,147

2,369

3,275

-

-

-

-

-

-

Loan payable, net of discount and current portion

-

-

-

-

-

-

7,827

7,706

9,698

9,922

10,127

Unearned income

-

-

-

-

-

-

1,318

1,519

1,796

1,936

2,054

Other liabilities

26

16

18

18

18

205

6

7

7

9

87

Total liabilities

34,926

31,478

30,430

37,339

33,108

21,621

18,004

19,446

20,798

22,547

24,328

Commitments and contingencies (Note 9)

-

-

-

-

-

-

0

0

-

-

0

Convertible preferred stock, $0.001 par value; 10,000,000 and 59,413,523 shares authorized as of December 31, 2019 and December 31, 2018, respectively; 0 and 40,079,567 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively

-

-

-

-

-

64,675

-

-

-

-

39,838

Stockholders’ equity:
Common stock, $0.001 par value. 33,333,333 shares authorized as of March 31, 2020 and December 31, 2019, respectively; 16,141,868 and 16,128,862 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

16

16

12

13

7

0

14

14

15

15

1

Common stock

16

16

12

13

7

0

-

-

-

-

-

Additional paid-in capital

262,076

261,367

200,421

199,690

119,521

2,151

153,667

152,601

151,396

150,830

991

Accumulated other comprehensive loss

-119

-119

-119

-42

23

0

144

177

-93

127

834

Accumulated deficit

-143,200

-132,044

-121,207

-103,493

-90,110

-79,237

-125,928

-115,028

-102,895

-92,265

-58,388

Total stockholders’ equity

118,791

129,220

79,107

96,168

29,441

-77,086

27,897

37,764

48,423

58,707

-56,562

Total liabilities and stockholders’ equity

153,717

160,698

109,537

133,507

62,549

9,944

45,901

57,210

69,221

81,254

7,604

Convertible Preferred Stock
Convertible preferred stock, $0.001 par value; 10,000,000 and 59,413,523 shares authorized as of December 31, 2019 and December 31, 2018, respectively; 0 and 40,079,567 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively

-

-

0

-

-

64,675

-

-

-

-

-

Redeemable Common Stock
Convertible preferred stock, $0.001 par value; 10,000,000 and 59,413,523 shares authorized as of December 31, 2019 and December 31, 2018, respectively; 0 and 40,079,567 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively

-

-

-

-

-

734

-

-

-

-

-

Common stock, $0.001 par value. 33,333,333 and 11,070,776 shares authorized as of September 30, 2019 and December 31, 2018, respectively; 12,436,205 and 351,652 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively

-

-

0

-

-

-

-

-

-

-

-

Redeemable Common Stock [Member]
Common stock

-

-

0

-

-

-

-

-

-

-

-